Results 151 to 160 of about 8,948 (223)

Use of blood-based neurofilament light chain as an endpoint in clinical trials of neurodegenerative conditions: a scoping review. [PDF]

J Neurol
Zheng Y, Bhalala OG, Chin KS, Watson R, Yassi N.   +4 more
europepmc   +1 more source

Improved Measurement of Treatment Effect in Multiple Sclerosis Clinical Trials.

JAMA Neurol
Signori A, Bovis F, Fedriga M, Montobbio N, Ponzano M, Schiavetti I, Sormani MP.   +6 more
europepmc   +1 more source

Selecting Informative Patients for Phase 2 Progressive Trials in MS: Design Considerations for Phase 2 Clinical Trials in Progressive MS. [PDF]

Mult Scler
Koch MW, Camara-Lemarroy C, Strijbis E, Mostert J, Leavitt VM, Repovic P, Bowen JD, Comtois J, Uitdehaag B, Cutter G.   +9 more
europepmc   +1 more source

Real-World Persistence with Ocrelizumab in Multiple Sclerosis: a Systematic Review. [PDF]

Neurol Ther
Petrie JL, Smith CA, Fountain D, Machnicki G.   +3 more
europepmc   +1 more source

[The presence of Ptolemy's Geography in Portuguese libraries: inventory, contextualisation and uses of an ancient scientific book]. [PDF]

Hist Cienc Saude Manguinhos
Maguelniski D, Bauab FP, Oliveira FR.
europepmc   +1 more source

Primary Progressive Multiple Sclerosis-A Key to Understanding and Managing Disease Progression. [PDF]

Int J Mol Sci
Sempik I, Dziadkowiak E, Moreira H, Zimny A, Pokryszko-Dragan A.   +4 more
europepmc   +1 more source

Should we stay or should we go? Recent insights on drug discontinuation in multiple sclerosis. [PDF]

Neurol Res Pract
Mrochen A, Meuth SG, Pfeuffer S.
europepmc   +1 more source

Long-Term Evaluation of Effectiveness and Immunological Implications of Ocrelizumab in a Real-World Cohort. [PDF]

Drugs Real World Outcomes
Guerra T, Caputo F, Bianco A, Paolicelli D, Iaffaldano P.   +4 more
europepmc   +1 more source

Oratorio prolétarien

Critical Move, 2015
openaire   +2 more sources